@article{JTD25863,
author = {Jiangtao Lin and Dong Yang and Mao Huang and Yongming Zhang and Ping Chen and Shaoxi Cai and Chuntao Liu and Changgui Wu and Kaisheng Yin and Changzheng Wang and Xin Zhou and Nan Su and on behalf of Asthma Workgroup of Chinese Thoracic Society, Chinese Medical Association, and China Asthma Alliance},
title = {Chinese expert consensus on diagnosis and management of severe asthma},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {12},
year = {2018},
keywords = {},
abstract = {Bronchial asthma (referred to as “asthma” hereinafter in this consensus document) is a chronic inflammatory airway disease with well-accepted heterogeneity and complex pathophysiological processes (1). Severe asthma is recognized as a poorly controlled condition that seriously affects quality of life, accounts for massive use of medical resources, and imposes huge socioeconomic burdens, representing a primary cause of asthma-related disability and death in the patients (2-5). In this regard, improving the diagnosis and treatment of severe asthma should be of paramount importance towards better outcomes in overall control and prognosis, as well as lower medical costs (5).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/25863}
}